Qualigen Corp - Wutah dodolan YoY (TTM) QLGN

Tandha merek Qualigen Corp (QLGN)

Qualigen Therapeutics (QLGN) faces high risks associated with its transition toward drug development and a capital deficit. This daily chart from the GURU.Markets platform illustrates the rolling annual change in sales volume, where the -9.00 level indicates the parameter's status. Outlooks are based on the creation of antiviral nanotechnologies to establish a long-term monopoly, while operational efficiency is supported by fully optimized supply chain logistics.

QLGN Qualigen Therapeutics Inc: Wutah dodolan YoY sajrone rolas wulan kepungkur ing interval 11.02.2024 - 20.02.2024

qualigeninc.com (QLGN) - rincian metrik lan laporan keuangan

- rega lan prakiraan konsensus rega:
Ringkesan analitik perusahaan:Qualigen Therapeutics
Produk mawa merek Qualigen Therapeutics

Developing antiviral drugs within the stable legal framework of the US minimizes external risks, allowing for a real-time assessment of the market expansion of Qualigen Therapeutics (QLGN). The current annual revenue growth for the rolling period at -9.00 measures TTM inflows, reflecting the business's ability to maintain market share and confirming the fundamental quality of asset management through the lens of competitive advantages.